We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Meibomian Gland Dysfunction Clinical Practice Guidelines.
- Authors
Amano, Shiro; Shimazaki, Jun; Yokoi, Norihiko; Hori, Yuichi; Arita, Reiko; Obata, Hiroto; Kawashima, Motoko; Koh, Shizuka; Suzuki, Takashi; Suzuki, Tomo; Yamaguchi, Masahiko; Yamada, Masakazu; Itokawa, Takashi; Iwashita, Hiroko; Usui, Tomohiko; Uchino, Miki; Oya, Fumika; Okajima, Yukinobu; Kaido, Minako; Kakisu, Koji
- Abstract
On the other hand, Giannaccare et al. [[192]] conducted a study on patients with MGD having subjective symptoms (OSDI>= 13) and at least one clinical sign of MGD, such as terminal ductal obstruction, plugging of the meibomian glands, turbid secretions, inflammation and swelling of the eyelid margins, or poor meibum secretions. One RCT [[423]] and two observational studies [[429]] assessed improvements in meibomian gland orifices and surrounding findings and report that minocycline oral administration can improve meibomian gland orifices and surrounding findings in patients with MGD and meibomitis. Additionally, Ibrahim et al. [[279]] show that meibomian gland acinar density, shortest and longest acinar diameter, and inflammatory cell density were significantly associated with BUT, fluorescein staining score, Rose Bengal staining, decreased lipid expression from the meibomian gland orifices, meibomian gland dropout, and ocular surface tear evaporation rate. In 22 patients without atrophy of the meibomian gland, after treatment with the cleansing agent, meibography indicated significant improvements in the meibomian gland orifices/surrounding findings (eyelid margin vascularity), quality of meibum, and BUT.
- Subjects
MEIBOMIAN glands; ROSACEA; EYE diseases; MEDICAL personnel; NUCLEAR magnetic resonance; INTRAOCULAR drug administration
- Publication
Japanese Journal of Ophthalmology, 2023, Vol 67, Issue 4, p448
- ISSN
0021-5155
- Publication type
Article
- DOI
10.1007/s10384-023-00995-8